<DOC>
	<DOCNO>NCT00594165</DOCNO>
	<brief_summary>The objective open-label extension ass safety tolerability long-term treatment rotigotine patch subject early-stage idiopathic Parkinson 's disease .</brief_summary>
	<brief_title>An Open-Label Extension Trial Assess Safety Long-Term Treatment Rotigotine Early-Stage Parkinson 's Disease .</brief_title>
	<detailed_description>This open-label extension randomize , double-blind , placebo-controlled SP512 trial assess efficacy safety tolerability Rotigotine patch subject early-stage idiopathic Parkinson 's Disease .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subjects complete six month maintenance treatment SP512 doubleblind trial Subjects ongoing serious adverse event SP512 doubleblind trial assess related study medication</criteria>
	<gender>All</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Rotigotine</keyword>
</DOC>